 |
16 Diseases |  |
0 Trials |
|
0 Trials |  |
23 News |  |
- || ulodesine (BCX4208) / BioCryst, Fodosine (forodesine) / Mundipharma, BioCryst
Review, Journal: Perspectives and challenges in developing small molecules targeting purine nucleoside phosphorylase. (Pubmed Central) - May 11, 2024
The most recent direction in PNP inhibitor development has been focused on PNP small-molecule inhibitors with better potency, selectivity, and pharmacokinetic property. In this perspective, considering the structure, biological functions, and disease relevance of PNP, we highlight the recent research progress in PNP small-molecule inhibitor development and discuss prospective strategies for designing additional PNP therapeutic agents.
- | ulodesine (BCX4208) / BioCryst
Journal: Chromosome 10q24.32 Variants Associate With Brain Arterial Diameters in Diverse Populations: A Genome-Wide Association Study. (Pubmed Central) - Dec 7, 2023
The current study reveals 3 novel risk loci (CNNM2, NT5C2, and AS3MT) associated with BADs. These findings may help elucidate the mechanism by which BADs may influence cerebrovascular health.
- | ulodesine (BCX4208) / BioCryst
Journal: A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis. (Pubmed Central) - Nov 21, 2023
These findings may help elucidate the mechanism by which BADs may influence cerebrovascular health. We also performed GWASs, which uncovered genetic variants associated with PN, including one near PLCB4 (rs6039266: OR
- ulodesine (BCX4208) / BioCryst
Variant Load in Childhood Nephrotic Syndrome Is Associated With Pattern of Therapy Response (Exhibit Hall, Orange County Convention Center, West Building) - Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3026;
Genotyping was done using TaqMan and Direct Sanger Sequencing for 10 childhood NS risk loci: HLA-DQA1 (rs1129740 & rs1071630), BTNL2 (rs9348883), HLA-DR/DQ (rs4642516 & rs3134996), Intergenic (rs9273371), CALHM6 (rs2637678), NPHS1/KIRREL (rs56117924), TNFSF15 (rs6478109), and TNFRSF11A (rs34213471)...Variant load was associated with both SRNS and FR/SD (SRNS vs. SSNS p=1.98e -15 and IFR vs. FR/SD p=0.002). Conclusion Our study showed that genetic risk loci for childhood NS are associated with pattern of therapy response and may predict disease outcome.
- | ulodesine (BCX4208) / BioCryst
Preclinical, Journal: Inosine induces acute hyperuricaemia in rhesus monkey (Macaca mulatta) as a potential disease animal model. (Pubmed Central) - Oct 30, 2021
Ulodesine, allopurinol and febuxostat eliminated the inosine-induced elevation in SUA in tested monkeys. An acute HUA animal model with high reproducibility was induced; it can be applied to evaluate new anti-HUA drugs in vivo and explore the disease pathogenesis.
- | ulodesine (BCX4208) / BioCryst
Journal: Association of polymorphisms in metastasis suppressor genes NME1 and KISS1 with breast cancer development and metastasis. (Pubmed Central) - May 25, 2021
Both EcoR1 (rs34214448) polymorphism of NME1 gene and rs5780218 polymorphism of KISS1 gene revealed significant association with increased risk of breast cancer development. The (G/G) genotype of EcoR1 polymorphism was associated with higher risk of breast cancer metastasis.
- | ulodesine (BCX4208) / BioCryst
Journal: A multi-omics study links TNS3 and SEPT7 to long-term former smoking NSCLC survival. (Pubmed Central) - May 20, 2021
We identified two SNPs, rs34211819 at 7p12.3 (P = 3.90 × 10) and rs1143149 at 7p14.2 (P = 9.75 × 10), were significantly associated with survival of NSCLC patients who were long-term former smokers...Pathway enrichment analysis indicated a unique pattern among long-term former smokers that was related to immune pathways. This study provides important insights into the genetic architecture associated with long-term former smoking NSCLC.
- ulodesine (BCX4208) / BioCryst
[VIRTUAL] EXPANDED GENOME-WIDE ASSOCIATION STUDY OF IBD IDENTIFIES OVER 80 NOVEL LOCI AND IMPLICATES NEW GENES AND PATHWAYS IN DISEASE SUSCEPTIBILITY (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_990;
Five of the associated regions contain genes implicated in monogenic autosomal recessive syndromes that include colitis: DOCK8, G6PC3, HPS4, NCF1, RAG1, and RAG2. Many risk loci causally alter the expression of nearby genes, suggesting that aberrant expression of these genes underpins the IBD association, including TNFRSF8, PLCG1-AS1, ITPKC and CSF1.
- ||| Tivicay (dolutegravir) / ViiV Healthcare, abacavir / Generic mfg.
Clinical, Journal, Adverse events: Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort. (Pubmed Central) - Jun 8, 2020
Although discontinuation for side effects was less frequent with dolutegravir than with boosted elvitegravir, discontinuation for NPAEs, although rare (2.7%), was more frequent with dolutegravir. No patient characteristic was found to be associated with these side effects in this very large population.
- |||| ulodesine (BCX4208) / BioCryst
Trial completion, Monotherapy: Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol (clinicaltrials.gov) - Oct 3, 2013
P2, N=279, Completed, Sponsor: BioCryst Pharmaceuticals
No patient characteristic was found to be associated with these side effects in this very large population. Active, not recruiting --> Completed
- | ulodesine (BCX4208) / BioCryst
Trial completion: A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency (clinicaltrials.gov) - Sep 17, 2012
P2, N=20, Completed, Sponsor: BioCryst Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | ulodesine (BCX4208) / BioCryst
Enrollment change: A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency (clinicaltrials.gov) - May 3, 2012
P2, N=20, Completed, Sponsor: BioCryst Pharmaceuticals
Active, not recruiting --> Completed N=40 --> 20
- |||| ulodesine (BCX4208) / BioCryst
Trial completion: A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis. (clinicaltrials.gov) - Sep 18, 2011
P2, N=66, Completed, Sponsor: Hoffmann-La Roche
N=40 --> 20 Active, not recruiting --> Completed